Deep sea as a source of novel-anticancer drugs
| dc.contributor.author | Russo, Patrizia | |
| dc.contributor.author | Del Bufalo, Alessandra | |
| dc.contributor.author | Fini, Massimo | |
| dc.date.accessioned | 2015-04-22T12:41:19Z | |
| dc.date.available | 2015-04-22T12:41:19Z | |
| dc.date.issued | 2015-02-10 | |
| dc.description.abstract | The deep-sea habitat is a source of very potent marine-derived agents that may inhibit the growth of human cancer cells “in vitro” and “in vivo”. Salinosporamide-A, Marizomib, by Salinispora species is a proteasome inhibitor with promising anticancer activity (Phase I/II trials). Different deep-sea-derived drugs are under preclinical evaluation. Cancer is a complex disease that may be represented by network medicine. A simple consequence is the change of the concept of target entity from a single protein to a whole molecular pathway and or cellular network. Deep-sea-derived drugs fit well to this new concept. | en |
| dc.identifier.issn | 1611-2156 | |
| dc.identifier.uri | http://hdl.handle.net/2003/34057 | |
| dc.identifier.uri | http://dx.doi.org/10.17877/DE290R-7879 | |
| dc.language.iso | en | |
| dc.relation.ispartofseries | EXCLI Journal ; Vol. 14, 2015 | en |
| dc.subject | deep-sea-derived drugs | en |
| dc.subject | cancer | en |
| dc.subject | systems medicine | en |
| dc.subject | network | en |
| dc.subject | therapy | en |
| dc.subject | preclinical studies | en |
| dc.subject | clinical studies | en |
| dc.subject.ddc | 610 | |
| dc.title | Deep sea as a source of novel-anticancer drugs | en |
| dc.title.alternative | Update on discovery and preclinical/clinical evaluation in a systems medicine perspective | en |
| dc.type | Text | |
| dc.type.publicationtype | article | |
| dcterms.accessRights | open access | |
| eldorado.dnb.zdberstkatid | 2132560-1 |